Plus   Neg

McDermott To Begin Chapter 11 Process; Agrees To Sell Lummus Technology

McDermott International, Inc. (MDR), a provider of technology, engineering and construction solutions to the energy industry, said the company intends to commence the prepackaged Chapter 11 filing in a U.S. Bankruptcy Court on Tuesday. The process will be financed by a debtor-in-possession financing facility of $2.81 billion.

Also, subsidiaries of McDermott have reached an agreement with a joint partnership between The Chatterjee Group and Rhône Group, under which the joint partnership is committed to acquire Lummus Technology for a base purchase price of $2.725 billion. McDermott plans to use the proceeds from the sale of Lummus to repay the DIP financing in full, as well as fund emergence costs. McDermott said it has secured committed exit financing of over $2.4 billion in letter of credit facility capacity and will emerge from Chapter 11 with approximately $500 million in funded debt.

"As a result of the transaction, we are eliminating over $4.6 billion in debt from our balance sheet and we will emerge with robust liquidity and significant financing. Throughout this process, McDermott will continue all business operations as normal," said David Dickson, CEO of McDermott.

The company expects to be delisted from the NYSE within the next 10 days. Its common stock will continue to trade in the over-the-counter marketplace throughout the process.

Shares of McDermott International, Inc. were down 14% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT